GSA Capital Partners LLP Buys Shares of 14,986,947 Gossamer Bio, Inc. $GOSS

GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,986,947 shares of the company’s stock, valued at approximately $2,467,000. GSA Capital Partners LLP owned approximately 0.06% of Gossamer Bio at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Kalehua Capital Management LLC bought a new position in shares of Gossamer Bio in the first quarter valued at approximately $3,363,000. State Street Corp increased its stake in shares of Gossamer Bio by 139.7% during the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after acquiring an additional 5,427,302 shares during the period. Corient Private Wealth LLC raised its holdings in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares in the last quarter. Millennium Management LLC raised its holdings in Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock worth $9,519,000 after purchasing an additional 3,123,081 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Gossamer Bio by 4,196.2% during the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock worth $7,579,000 after purchasing an additional 2,814,824 shares in the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GOSS shares. Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price objective on the stock in a research note on Tuesday, July 28th. Finally, HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a report on Monday, July 27th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.20.

Gossamer Bio Trading Down 9.5%

NASDAQ:GOSS opened at $0.15 on Friday. The company has a 50-day moving average of $0.17 and a 200-day moving average of $0.57. The firm has a market cap of $36.19 million, a price-to-earnings ratio of -0.22 and a beta of 2.04. Gossamer Bio, Inc. has a twelve month low of $0.11 and a twelve month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $9.24 million during the quarter, compared to the consensus estimate of $3.63 million. On average, research analysts forecast that Gossamer Bio, Inc. will post -0.39 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.